On this page
Portrazza
necitumumab
351(a) Standalone BLA
Overview
Source: Purple BookProprietary name
Portrazza
Proper name
necitumumab
Licence type
351(a)
BLA number
125547
Applicant
Eli Lilly and Company
Center
CDER
Presentations
1
First licensure
—
Presentations
Source: Purple Book| Strength | Dosage form | Route | Presentation | Status | Licensed |
|---|---|---|---|---|---|
| 800MG/50ML (16MG/ML) | Injection | Intravenous | Single-Dose Vial | Rx | November 24, 2015 |
Exclusivity
Source: Purple Book| Kind | Expires |
|---|---|
| Orphan exclusivity | November 24, 2022 |
Sources for this page
| Purple Book | FDA | Licence type, presentations, reference product, exclusivity |